Darya-Varia Laboratoria Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Darya-Varia Laboratoria Tbk PT with three other
pharmaceutical manufacturers in Asia:
Sanofi Aventis Pakistan Ltd
sales of 8.79 billion Pakistan Rupees [US$87.56 million]
of which 100%
Biofermin Pharmaceutical Company Limited
(10.31 billion Japanese Yen [US$86.91 million]
of which 100%
was Drug Manufacturing), and
Shandong JinTai Group Co., Ltd.
based in China
(537.93 million Chinese Renmimbi [US$86.81 million]
of which 99%
was Gold and Jewery).
During the year ended December of 2013, sales at
Darya-Varia Laboratoria Tbk PT were 1.10 trillion Indonesian Rupiahs (US$87.03 million).
a very small
increase of 1.3%
versus 2012, when the company's sales were 1.09 trillion Indonesian Rupiahs.
This was the fifth consecutive year of sales increases at Darya-Varia Laboratoria Tbk PT
(and since 2008, sales have increased a total of 91%).
Sales of Consumer Health saw an increase
that was more than double the company's growth rate: sales were up
9.6% in 2013, from
359.47 billion Indonesian Rupiahs to 393.83 billion Indonesian Rupiahs.
Not all segments of Darya-Varia Laboratoria Tbk PT experienced an increase in sales in 2013:
sales of Prescribed Medicines fell 2.9% to 514.67 billion Indonesian Rupiahs.
Darya-Varia Laboratoria Tbk PT also experienced decreases in sales in
Toll Manufacturing (down 2.4% to 193.19 billion Indonesian Rupiahs)